Drugs / TSN1611
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06385925 | Apr 2024 → Oct 2026 expected | cancer | Tyligand Pharmaceuticals (Suzhou) Limited | Recruiting | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-31 | Tyligand Bioscience (Shanghai) Limited | Tyligand Bioscience Presents the Latest Data for TSN1611 in KRAS G12D-Mutated Non-Small Cell Lung Cancer at the 2026 ASCO Rapid Oral Abstract Session tyligand.com.cn ↗ |
| 2026-05-29 | Tyligand Bioscience (Shanghai) Limited | Tyligand Bioscience's KRAS G12D Inhibitor TSN1611 Selected for 2026 ASCO Rapid Oral Abstract Session tyligand.com.cn ↗ |
| 2026-01-12 | Tyligand Bioscience (Shanghai) Limited | Tyligand Bioscience Presents the Latest Clinical Data of KRAS G12D Inhibitor TSN1611 at the 2026 ASCO GI tyligand.com.cn ↗ |
| 2024-05-17 | Tyligand Bioscience (Shanghai) Limited | Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor tyligand.com.cn ↗ |
| 2024-04-05 | Tyligand Bioscience (Shanghai) Limited | Tyligand Bioscience Presents Preclinical Data on FDA IND-Cleared KRAS G12D Inhibitor TSN1611 at the 2024 AACR Annual Meeting tyligand.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSN1611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06385925 ↗ |
| Route | Oral | “administered at the assigned dose level, orally” NCT06385925 ↗ |